Resources

Resources

{site_title}

Thromboxane-dependent CD40 ligand release in type II diabetes mellitus

"The goals of this study were to characterize the platelet contribution to soluble CD-40 ligand (sCD40L), to correlate its formation with the extent of oxidative stress and platelet activation, and to investigate the effects of improved metabolic control and low-dose aspirin on these processes."

“This study provides several lines of evidence for the dependence of sCD40L release on TXA2-dependent platelet activation in T2DM and provides novel mechanistic insight into the amplification loops of persistent platelet activation in this setting.”

Read More

The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients

Diabetic patients may have a higher prevalence of platelet aspirin resistance than nondiabetic patients.  Our goal was to analyze platelet aspirin responsiveness to various aspirin doses in diabetic and nondiabetic patients."

“Diabetic patients with CAD treated with 81 mg aspirin exhibit a higher prevalence of aspirin resistance and have significantly higher ADP- and collagen-induced platelet aggregation, 11-DHXTB2 levels, and aspirin reaction units measured by Verify Now than nondiabetic patients.”

Read More

Thromboxane biosynthesis and platelet function in type II diabetes mellitus

“Tight metabolic control achieved with insulin therapy reduced the levels of 11-dehydro-thromboxane B2 by approximately 50 percent.”

“Aspirin in low doses (50 mg per day for seven days) reduced urinary excretion of the metabolite by approximately 80 percent in four patients.”

Read More

Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus

“Compared with non-diabetics, patients with Type II diabetes mellitus (T2Dm) have a two-to four-fold increased risk of ischemic cardiovascular disease, a risk largely independent of concomitant hypertension, hypercholesterolemia, and smoking.”

Read More

Changes of thromboxane A2 (TXA2) and prostacyclin (PGI2) in COPD patients with pulmonary hypertension

"We measured the pulmonary arterial pressure and the level of Thromboxane A2 (TXA2), and Prostacyclin (PGI2) in 30 stable COPD patients and the level of TXA2 and PGI2 in 10 normal subjects so as to investigate the changes of TXA2 and PGI2 in COPD patients with pulmonary hypertension."

“The results showed that the level of TXA2 increased significantly in COPD patients with dominant and latent pulmonary hypertension when compared with that in normal subjects.”

Read More

Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease

“The urinary excretion of 11-dehydro-TxB2 was significantly higher in patients with COPD than in control subjects. Moreover, 11-dehydro-TxB2 excretion was inversely related with arterial oxygen tension.”

Read More

Inflammation and platelet activation in peripheral arterial occlusive disease.

"Epidemiological evidence indicates that inflammation accompanies the progression of atherosclerosis.  The aim of the present cross-sectional study was to define relationships between platelet activation and inflammation in patients with mild to severe (stages II to IV) peripheral arterial occlusive disease (PAOD) and matched controls.  The effect of chronic administration of low-dose acetylsalicylic acid was investigated."

“A positive correlation between 11-DHTXB2 and CRP was found in the study population.”

Read More

Mechanisms of atherothrombosis in chronic obstructive pulmonary disease.

"Chronic obsructive pulmonary disease (COPD) is a leading cause of death worldwide. (Calverley and Walker 2003) In addition to the healthcare costs, COPD imposes a significant burden in terms of disability and impaired quality of life.  Unlike many other leading causes of death and disability, COPD prevalence will raise in the majority of countries as smoking frequency increses and the population ages. (Halbert et al 2006). The World Health Organization predicts that by 2020 COPD will be the 5th most prevalent disease worldwide and the 3rd most common cause of death. "

“CPR upregulates the production of pro-inflammatory cytokines and tissue factor by monocytes, increases the uptake of low-density lipoproteins (LDL by macrophages with foam cells formation and directly induces expression of adhesion molecules by human endothelial cells.”

Read More

Prostanoid and TP-receptors in atherothrombosis: Is there a role for their antagonism?

"Atherosclerosis and its clinical manifestations (i.e. myocardial infarction, stroke) are major causes of mortality and morbidity in Western countries.  Atherogenesis is a pathological process characterised by the deposition of lipids and other blood-borne materials in the arterial wall.  Endothelial dysfunction is considered the first step in the cascade leading up to coronary events."

“Dysfunctional endothelium, characterized by increased COX-activity, releases prostanoids that promote endothelial exposure to adhesion molecules and induce smooth muscle cell contraction.”

Read More

Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population.

"Resistance to inhibition of platelet function by aspirin may contribute to future myocardial infarction and stroke.  Adverse cardiovascular outcomes have been associated with aspirin resistance on several different platelet function assays, including the level of urinary 11-dehydro thromboxane B2 (Tx-M), platelet aggregation to arachidonic acid and adenosine diphosphate, and closure time on the platelet function analyzer-100.  We examined the concordance of these aspirin-resistance assays and their relation to cardiovascular risk factors in a primary prevention population."

“Aspirin resistance by platelet function analyzer-100 was associated only with increased von Willebrand factor levels and not with atherosclerotic risk profile.”

Read More